Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 101

The DOI matches its Crossref record.

Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: A meta-analysis

Rahimi, Roja, Nikfar, Shekoufeh, Abdollahi, Mohammad·2009·Progress in Neuro-Psychopharmacology and Biological Psychiatry
DOI 10.1016/j.pnpbp.2008.10.018
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pnpbp.2008.10.018

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 24

  1. Behnke, 2002, Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression, Adv Ther, 19, 43, 10.1007/BF02850017 · DOI
  2. Bjerkenstedt, 2005, Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients, Eur Arch Psychiatry Clin Neurosci, 255, 40, 10.1007/s00406-004-0532-z · DOI
  3. Brenner, 2000, Comparison of an extract of Hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study, Clin Ther, 22, 411, 10.1016/S0149-2918(00)89010-4 · DOI
  4. Butterweck, 2007, St. John's wort: role of active compounds for its mechanism of action and efficacy, Wien Med Wochenschr, 157, 356, 10.1007/s10354-007-0440-8 · DOI
  5. E/S/C/O/P Monographs, 2nd ed. the European Scientific Cooperative on Phytotherapy in collaboration with Thieme: 2003.
  6. Di, 2008, Clinical drugs that interact with St. John's wort and implication in drug development, Curr Pharm Des, 14, 1723, 10.2174/138161208784746798 · DOI
  7. Fava, 2005, A double-blind, randomized trial of St. John's wort, fluoxetine, and placebo in major depressive disorder, J Clin Psychopharmacol, 25, 441, 10.1097/01.jcp.0000178416.60426.29 · DOI
  8. Gastpar, 2005, Efficacy and tolerability of Hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline, Pharmacopsychiatry, 38, 78, 10.1055/s-2005-837807 · DOI
  9. Gastpar, 2006, Comparative efficacy and safety of a once-daily dosage of Hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study, Pharmacopsychiatry, 39, 66, 10.1055/s-2006-931544 · DOI
  10. Harrer, 1999, Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine, Arzneimittelforschung, 49, 289
  11. Hypericum Depression Trial Study Group, 2002, Effect of Hypericum perforatum (St. John's wort) in major depressive disorder: a randomized controlled trial, JAMA, 287, 1807, 10.1001/jama.287.14.1807 · DOI · Paper page
  12. Kalb, 2001, Efficacy and tolerability of Hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trial, Pharmacopsychiatry, 34, 96, 10.1055/s-2001-14280 · DOI
  13. Kasper, 2006, Superior efficacy of St. John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298], BMC Med, 4, 14, 10.1186/1741-7015-4-14 · DOI
  14. Lecrubier, 2002, Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial, Am J Psychiatry, 159, 1361, 10.1176/appi.ajp.159.8.1361 · DOI
  15. Linde, 2005, St. John's wort for depression: meta-analysis of randomised controlled trials, Br J Psychiatry, 186, 99, 10.1192/bjp.186.2.99 · DOI
  16. Linde, 2005, St. John's wort for depression, Cochrane Database Syst Rev, 2, CD000448
  17. Moreno, 2006, Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sample, Rev Bras Psiquiatr, 28, 29, 10.1590/S1516-44462006000100007 · DOI
  18. Papakostas, 2007, Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. A replication of findings with the use of a double-blind, placebo-controlled trial of Hypericum perforatum versus fluoxetine, Neuropsychobiology, 56, 132, 10.1159/000115779 · DOI
  19. Rahimi, 2006, Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials, Reprod Toxicol, 22, 571, 10.1016/j.reprotox.2006.03.019 · DOI
  20. Rahimi, 2008, Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials, Arch Med Sci, 4, 71
  21. Rahimi, 2008, Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials, Clin Ther, 30, 884, 10.1016/j.clinthera.2008.05.002 · DOI
  22. Schrader, 2000, Equivalence of St. John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression, Int Clin Psychopharmacol, 15, 61, 10.1097/00004850-200015020-00001 · DOI
  23. Szegedi, 2005, Acute treatment of moderate to severe depression with Hypericum extract WS 5570 (St. John's wort): randomised controlled double blind non-inferiority trial versus paroxetine, BMJ, 330, 503, 10.1136/bmj.38356.655266.82 · DOI
  24. van Gurp, 2002, St. John's wort or sertraline? Randomized controlled trial in primary care, Can Fam Physician, 48, 905

Cited by

Metadata

Authors
Rahimi, R., Nikfar, S., & Abdollahi, M.
Venue
Progress in Neuro-Psychopharmacology and Biological Psychiatry
Publisher
Elsevier BV
Published
2009-02
Volume
33
Issue
1
Pages
118-127
ISSN
0278-5846
DOI
10.1016/j.pnpbp.2008.10.018
Cited by
101
References
0
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.